*************ANOTHER PRESS RELEASE************
=====================================================================(BSNS WIRE) Advanced Optics Electronics Inc. Announces: BioModa Inc. ''H
Advanced Optics Electronics Inc. Announces: BioModa Inc. ''Human Clinical
Testing Shows Value of New Diagnostic for Early Detection of Lung Cancer''
Business Editors
ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Nov. 16, 1998--BioModa Inc.
Monday announced the successful completion of the first commercial
clinical testing of its TCPP lung cancer diagnostic.
An independent, commercial lung cytology laboratory performed the
tests. The blinded study has proven that BioModa's technology is now
ready to move into the commercialization phase. The company expects to
have its test kit in the marketplace by the end of the first quarter
of 1999.
"This is the validation we've been waiting for. Now it's full
speed ahead with the kit," stated Ari Ma'ayan, BioModa's president.
BioModa had hoped that the testing would validate the company's
conclusion from earlier laboratory work that the technology would be
capable of detecting early stages of pre-cancerous conditions of the
lung. "The trials have done exactly that," said BioModa's Chief
Technical Officer, Jeff Garwin, M.D., Ph.D.
"The key to raising the survival rate for any type of cancer is
early detection, and up until now there was no test which could
accurately, quickly and inexpensively detect patterns of abnormal
cells in the lung which could develop into lung cancer. This test
should detect those patterns several years before any other diagnostic
modality," stated Dr. Garwin.
Early detection could raise the 5-year survival rate of lung
cancer from 15 percent to 46 percent, and new preventive treatments
may be able to halt the progression to lung cancer, if pre-cancerous
conditions are detected early enough. Lung cancer strikes nearly
200,000 Americans each year and is the leading cause of cancer death
in the United States and the world.
BioModa's core technology was developed at Los Alamos National
Laboratory and St. Mary's Medical Center in Grand Junction, Colo.
BioModa received an exclusive worldwide license to the technology in
1995.
The technology is protected by patents, which have issued in the
United States and several foreign countries and which are pending in
several more. Additionally, the company will file a number of
important new patents in the near future.
BioModa now intends to start developing products to image and
treat lung cancer, based on its exclusive core technology. The company
also plans to extend its technology to develop diagnostic tests and
treatments for other cancers. Plans call for entering into
partnerships with U.S.- and foreign-based corporations for R&D,
production, marketing and distribution.
Advanced Optics Electronics Inc. currently owns 22.8 percent of
BioModa Inc. with an option, if fully exercised which allows Advanced
Optics Electronics Inc. position to move to approximately 26.5 percent
of BioModa Inc.
Advanced Optics Company Information
Advanced Optics Electronics Inc. (OTC BB:ADOT news) is a
developer of patented electronic display technology, utilizing ADOT's
proprietary SLM (Spatial Light Modulator) light valve.
This industry-leading technology can be utilized in many diverse
fields including the production of "television quality" advertising
billboards, medical testing equipment, military displays, computer
monitors and high definition video transmission.
Shareholder Relations Note
ADOT will promptly respond to all requests for information from
shareholders and the general public; shareholders will receive
priority response. All such requests must be sent to ADOT via
FAX: 505/858-1871 or U.S. Mail to 8301 Washington Ave. Building 4,
Albuquerque, NM 87113. All such requests must include the name,
daytime fax (if available) and street address as box numbers cannot
be accepted.
This policy is necessitated by the very large number of Internet
postings and inquiries, many with pen names which have caused ADOT and
other related companies to be overwhelmed with anonymous comments,
requests and demands.
This news release contains forward-looking statements with
respect to the results of operations and business of the company that
involves risk and uncertainties. The company's actual future results
could materially differ from those discussed. Risks and uncertainties
of the company will be detailed from time to time in the company's
periodic reports to be filed with the Securities and Exchange
Commission.
Contact Advanced Optics Electronics Inc. at 505/797-7878 or visit
their Web site at www.adot.org.
--30--kjs/ix* dlc/ix
CONTACT: Advanced Optics Electronics Inc., Albuquerque
505/797-7878
www.adot.org
KEYWORD: NEW MEXICO
INDUSTRY KEYWORD: COMPUTERS/ELECTRONICS COMED MEDICINE
BIOTECHNOLOGY PRODUCT
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com
|
